Carotid plaque constituents such as hemorrhage, lipid core, fibrosis, and calcification are important factors in predicting the clinical outcome of carotid artery stenting (CAS). Magnetic resonance imaging (MRI) can noninvasively assess changes in carotid plaque composition by evaluating the Sp/Sm ratio calculated with the signal intensity of carotid plaque (Sp) compared to that of sternocleidomastoid muscle (Sm) using the black-blood technique.
In the current study, we assessed the effects of 5 mg rosuvastatin and 1,800 mg eicosapentaenoic acid (EPA) on carotid plaque composition and volume using MRI and intravascular ultrasound prior to CAS. Thirty consecutive patients with atherosclerotic carotid stenosis were randomly divided into two groups-an EPA/rosuvastatin group (n=15) and a control group (n=15)-and then were treated with CAS. Perioperative complications and postoperative high spotty lesions on diffusion weighted image (DWI) were compared between the two groups. As a result, EPA and rosuvastatin significantly reduced the Sp/Sm ratio in both T1-and T2-weighted images in patients with unstable plaques (T1; p=0.021, T2; p=0.014). Plaque volume was also reduced between baseline and follow-up in 4 of 15 cases treated with EPA/rosuvastatin. The number of postoperative high spotty lesions on DWI significantly decreased in the EPA/rosuvastatin group (13%; 2/15) compared with the control group (40%; 6/15, p 0.05), whereas no significant difference was observed in perioperative complication rate.
The combined therapy of EPA and rosuvastatin leads to a benefical effect on plaque composition and volume, which may contribute to reducing the ischemic complications with CAS, particular in patients with vulnerable plaque. A manual operator-defined region of interest (ROI) was drawn on a workstation to refer to the plaque component, and the Sp/Sm ratio at the corresponding location on the matched MR image was measured. The Sp/Sm ratio on T1-and T2-weighted images was 3.0 and 1.2 for group I, respectively. 1.0 and 3.5 for group II, 2.8 and 3.2 for group III, 0.8 and 0.9 for group IV. Each intraoperative photo matched to axial MR images corresponds to intraplaque hemorrhage (arrow in I), lipid core (arrowhead in II), intraplaque hemorrhage (arrow in III) and lipid core (arrowhead in III), and fibrous or calcified plaque (dotted circle in IV), respectively. Asterisk indicates the lumen of carotid artery; SCM, sternocleidomastoid muscle; JV, jugular vein. each patient without EPA/rosuvastatin from baseline to 1 month of follow-up. No significant difference in Sp/Sm ratio between baseline and follow-up was observed in both T1-and T2-weighted images using one-sample t test. NS: not significant Fig. 4 Scattergram of changes in Sp/Sm ratio on T1-( ) and T2-weighted images ( ) for each patient treated with EPA/rosuvastatin from baseline to median follow-up period of 42 days (top row). Comparison of baseline T1-and T2-weighted images of carotid plaque with the follow-up same images after EPA/rosuvastatin treatment (bottom row). Notice that the hyperintense signal on T1-(arrow) and T2-weighted images (arrowhead) from the baseline scans has changed into hypointense signal at follow-up scans after EPA/rosuvastatin treatment in the right carotid artery. The Sp/Sm ratio was significantly reduced after EPA/rosuvastatin intake in both T1-(p 0.021) and T2-weighted images (p 0.014) in the patients with unstable plaques. SCM: sternocleidomastoid muscle, JV: jugular vein 
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